The iCHIP® Solution
The SLE-key® Rule Out test is based on the ImmunArray iCHIP®, a groundbreaking in-vitro autoantibody profiling platform. The iCHIP® provides a detailed view of the immune system based on a panel of 200 printed antigens. iCHIP® data can provide either a snapshot of a single time point or be used to monitor autoantibody profiles over time. Profiling over time may be used to monitor and predict disease, and treatment outcomes.
Technology Platform
iCHIP®s are printed antigen microarrays with 100s of antigens. Proprietary analytics are utilized to monitor iCHIP® manufacturing, and for identifying and interpreting antibody signatures. The iCHIP® Technology includes customizable application chips with 100s of antigens, granting flexibility in potential diagnostic capabilities outside of SLE. iCHIP® is a scalable chip manufacturing platform that is amendable to automation, and allows for sensitive and specific testing and readout procedure.
| iCHIP® Technology Platform A proprietary microarray of antigens |
iCHIP® Products |
|
|
⇒ |
|
Precision Medicine
ImmunArray uses commercially-available readers for fluorescence detection and analysis, proprietary software to analyze antibody signal and profile responses, and a proprietary database to interpret responses for a particular disease application. Future products using the iCHIP® technology are aimed at immuno-oncology, traumatic brain injury, transplantation medicine, multiple sclerosis, and other disorders. Testing is performed in company-owned service laboratory facility in Richmond Virginia.
The iCHIP® proprietary technology is potentially a significant improvement over current precision medicine alternatives as it:
- requires minimal sample volume
- potentially identifies disease prior to irreversible injury
- predicts response prior to therapy
- objectively defines uniform clinical trial phenotypes
- may accelerate development via defining responsive cohorts
- provides for early termination of ineffective candidate compounds
Use of an iCHIP® in immune-mediated diseases may mirror the increasingly common trend favoring use of companion diagnostics (providing essential information regarding safe and effective use of a particular therapeutic product). Autoantibody response assays could become a requirement in the development of selected drugs, turning into a ‘gatekeeper’ for reimbursement.
The iCHIP® assesses the immune system, creating the potential for optimized, patient-specific diagnosis and therapy management (“Precision Medicine”).
iCHIP® tests evaluate the immune system as a whole:
- Analysis via the immune system’s autoantibody response profile
- Potentially enables dynamic monitoring longitudinally
- Identification of diseases prior to irreversible damage
- Prediction of response prior to therapy and monitoring of therapeutic response